JARED NELSON: Open Payments
NPI 1295091791 · RIALTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$921 in 44 payments from 8 companies in 2025. Trend: 2023 $314 · 2024 $476 · 2025 $921
Food & beverage: $921
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 10 | $259 |
| E.R. Squibb & Sons, L.L.C. | 10 | $191 |
| Teva Pharmaceuticals USA, Inc. | 6 | $125 |
| Janssen Pharmaceuticals, Inc | 6 | $95 |
| Alkermes, Inc. | 4 | $90 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| Luye Pharma (USA) Ltd. | 3 | $47 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $28 |
Products named: INGREZZA, COBENFY, AUSTEDO XR, INVEGA SUSTENNA, ARISTADA, ABILIFY ASIMTUFII, ERZOFRI EXTENDED-RELEASE, CAPLYTA.
Industry payments across CA — which companies pay providers there.
